Peroxisome proliferator-activated receptor γ decouples fatty acid uptake from lipid inhibition of insulin signaling in skeletal muscle

Molecular Endocrinology

Volumn 26, Issue 6, 2012, Pages 977-988

  Hu, Shanming ^a   Yao, Jianrong ^a   Howe, Alexander A ^a   Menke, Brandon M ^a   Sivitz, William I ^a,b   Spector, Arthur A ^a   Norris, Andrew W ^a  

^a Department of Pediatrics ^*  (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Ligands; Nuclear receptors; PPAR ; Rosiglitazone

Indexed keywords

CD36 ANTIGEN; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; CONTROLLED STUDY; ELECTROPORATION; FATTY ACID TRANSPORT; GLYCOGEN SYNTHESIS; IN VIVO STUDY; INSULIN METABOLISM; INSULIN SIGNALING; MOUSE; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

ANIMALS; ANTIGENS, CD36; CELL LINE; FATTY ACIDS; GLUCOSE; GLYCOGEN; INSULIN; LIPID METABOLISM; MICE; MICE, INBRED C57BL; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; OLEIC ACID; OXIDATION-REDUCTION; PHOSPHOLIPIDS; PHOSPHORYLATION; PPAR GAMMA; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; UP-REGULATION;

MURINAE; MUS;

EID: 84861215127     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2011-1253     Document Type: Article

References (51)

1. Gouda HN, Sagoo GS, Harding AH, Yates J, Sandhu MS, Higgins JP 2010 The association between the peroxisome proliferator-activated receptor-γ2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. Am J Epidemiol 171:645-655
2. Petersen KF, Krssak M, Inzucchi S, Cline GW, Dufour S, Shulman GI 2000 Mechanism of troglitazone action in type 2 diabetes. Diabetes 49:827-831
3. Loviscach M, Rehman N, Carter L, Mudaliar S, Mohadeen P, Ciaraldi TP, Veerkamp JH, Henry RR 2000 Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action. Diabetologia 43:304-311
4. Kruszynska YT, Mukherjee R, Jow L, Dana S, Paterniti JR, Olefsky JM 1998 Skeletal muscle peroxisome proliferatoractivated receptor- expression in obesity and noninsulin-dependent diabetes mellitus. J Clin Invest 101:543-548
5. Lapsys NM, Kriketos AD, Lim-Fraser M, Poynten AM, Lowy A, Furler SM, Chisholm DJ, Cooney GJ 2000 Expression of genes involved in lipid metabolism correlate with peroxisome proliferator-activated receptor γ expression in human skeletal muscle. J Clin Endocrinol Metab 85:4293-4297
6. Hevener AL, Olefsky JM, Reichart D, Nguyen MT, Bandyopadyhay G, Leung HY, Watt MJ, Benner C, Febbraio MA, Nguyen AK, Folian B, Subramaniam S, Gonzalez FJ, Glass CK, Ricote M 2007 Macrophage PPARγ is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest 117:1658-1669
7. Norris AW, Chen L, Fisher SJ, Szanto I, Ristow M, Jozsi AC, Hirshman MF, Rosen ED, Goodyear LJ, Gonzalez FJ, Spiegelman BM, Kahn CR 2003 Muscle-specific PPARγ-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 112:608-618
8. Hevener AL, He W, Barak Y, Le J, Bandyopadhyay G, Olson P, Wilkes J, Evans RM, Olefsky J 2003 Muscle-specific Pparg deletion causes insulin resistance. Nat Med 9:1491-1497
9. Tontonoz P, Spiegelman BM 2008 Fat and beyond: the diverse biology of PPARγ. Annu Rev Biochem 77:289-312
10. Norris AW, Hirshman MF, Yao J, Jessen N, Musi N, Chen L, Sivitz WI, Goodyear LJ, Kahn CR 2008 Endogenous peroxisome proliferator-activated receptor-γ augments fatty acid uptake in oxidative muscle. Endocrinology 149:5374-5383
11. Blaak EE 2004 Basic disturbances in skeletal muscle fatty acid metabolism in obesity and type 2 diabetes mellitus. Proc Nutr Soc 63:323-330
12. Ibrahimi A, Bonen A, Blinn WD, Hajri T, Li X, Zhong K, Cameron R, Abumrad NA 1999 Muscle-specific overexpression of FAT/ CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin. J Biol Chem 274:26761-26766
13. Goudriaan JR, Dahlmans VE, Teusink B, Ouwens DM, Febbraio M, Maassen JA, Romijn JA, Havekes LM, Voshol PJ 2003 CD36 deficiency increases insulin sensitivity in muscle, but induces insulin resistance in the liver in mice. J Lipid Res 44:2270-2277
14. Fang X, Hu S, Watanabe T, Weintraub NL, Snyder GD, Yao J, Liu Y, Shyy JY, Hammock BD, Spector AA 2005 Activation of peroxisome proliferator-activated receptor α by substituted urea-derived soluble epoxide hydrolase inhibitors. J Pharmacol Exp Ther 314: 260-270
15. Yu S, Matsusue K, Kashireddy P, Cao WQ, Yeldandi V, Yeldandi AV, Rao MS, Gonzalez FJ, Reddy JK 2003 Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor γ1 (PPARγ1) overexpression. J Biol Chem 278:498-505
16. Mauvais-Jarvis F, Virkamaki A, Michael MD, Winnay JN, Zisman A, Kulkarni RN, Kahn CR 2000 A model to explore the interaction between muscle insulin resistance and β-cell dysfunction in the development of type 2 diabetes. Diabetes 49:2126-2134
17. Folch J, Lees M, Sloane Stanley GH 1957 A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226:497-509
18. Signorelli P, Hannun YA 2002 Analysis and quantitation of ceramide. Methods Enzymol 345:275-294
19. Bligh EG, Dyer WJ 1959 A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37:911-917
20. Ueki K, Yamauchi T, Tamemoto H, Tobe K, Yamamoto-Honda R, Kaburagi Y, Akanuma Y, Yazaki Y, Aizawa S, Nagai R, Kadowaki T 2000 Restored insulin-sensitivity in IRS-1-deficient mice treated by adenovirus-mediated gene therapy. J Clin Invest 105:1437-1445
21. Wu M, Neilson A, Swift AL, Moran R, Tamagnine J, Parslow D, Armistead S, Lemire K, Orrell J, Teich J, Chomicz S, Ferrick DA 2007 Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Physiol Cell Physiol 292:C125-C136
22. Finck BN, Bernal-Mizrachi C, Han DH, Coleman T, Sambandam N, LaRiviere LL, Holloszy JO, Semenkovich CF, Kelly DP 2005 A potential link between muscle peroxisome proliferator- activated receptor- signaling and obesity-related diabetes. Cell Metab 1:133-144
23. Tanaka T, Yamamoto J, Iwasaki S, Asaba H, Hamura H, Ikeda Y, Watanabe M, Magoori K, Ioka RX, Tachibana K, Watanabe Y, Uchiyama Y, Sumi K, Iguchi H, Ito S, Doi T, Hamakubo T, Naito M, Auwerx J, Yanagisawa M, Kodama T, Sakai J 2003 Activation of peroxisome proliferator-activated receptor induces fatty acid α-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA 100:15924-15929
24. kb activation and insulin resistance in skeletal muscle cells. Endocrinology 151:1560-1569
25. Sauerberg P, Olsen GS, Jeppesen L, Mogensen JP, Pettersson I, Jeppesen CB, Daugaard JR, Galsgaard ED, Ynddal L, Fleckner J, Panajotova V, Polivka Z, Pihera P, Havranek M, Wulff EM 2007 Identification and synthesis of a novel selective partial PPARσ agonist with full efficacy on lipid metabolism in vitro and in vivo. J Med Chem 50:1495-1503
26. Muoio DM, Way JM, Tanner CJ, Winegar DA, Kliewer SA, Houmard JA, Kraus WE, Dohm GL 2002 Peroxisome proliferator-activated receptor- αregulates fatty acid utilization in primary human skeletal muscle cells. Diabetes 51:901-909
27. Bastie CC, Hajri T, Drover VA, Grimaldi PA, Abumrad NA 2004 CD36 in myocytes channels fatty acids to a lipase-accessible triglyceride pool that is related to cell lipid and insulin responsiveness. Diabetes 53:2209-2216
28. Leesnitzer LM, Parks DJ, Bledsoe RK, Cobb JE, Collins JL, Consler TG, Davis RG, Hull-Ryde EA, Lenhard JM, Patel L, Plunket KD, Shenk JL, Stimmel JB, Therapontos C, Willson TM, Blanchard SG 2002 Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41:6640-6650
29. Casamayor A, Morrice NA, Alessi DR 1999 Phosphorylation of Ser-241 is essential for the activity of 3-phosphoinositide-dependent protein kinase-1: identification of five sites of phosphorylation in vivo. Biochem J 342(Pt 2):287-292
30. Sablina AA, Hector M, Colpaert N, Hahn WC 2010 Identification of PP2A complexes and pathways involved in cell transformation. Cancer Res 70:10474-10484
31. Du K, Herzig S, Kulkarni RN, Montminy M 2003 TRB3: A tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science 300:1574-1577
32. Wang C, Liu M, Riojas RA, Xin X, Gao Z, Zeng R, Wu J, Dong LQ, Liu F 2009 Protein kinase Co (PKCo)-dependent phosphorylation of PDK1 at Ser504 and Ser532 contributes to palmitate-induced insulin resistance. J Biol Chem 284:2038-2044
33. Labbé SM, Croteau E, Grenier-Larouche T, Frisch F, Ouellet R, Langlois R, Guérin B, Turcotte EE, Carpentier AC 2011 Normal postprandial nonesterified fatty acid uptake in muscles despite increased circulating fatty acids in type 2 diabetes. Diabetes 60:408-415
34. Kelley DE, Simoneau JA 1994 Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus. J Clin Invest 94:2349-2356
35. Digel M, Staffer S, Ehehalt F, Stremmel W, Ehehalt R, Füllekrug J 2011 FATP4 contributes as an enzyme to the basal and insulin mediated fatty acid uptake of C2C12 muscle cells. Am J Physiol Endocrinol Metab 301:E785-E796
36. Sato O, Kuriki C, Fukui Y, Motojima K 2002 Dual promoter structure of mouse and human fatty acid translocase/CD36 genes and unique transcriptional activation by peroxisome proliferator-activated receptor α and γ ligands. J Biol Chem 277:15703-15711
37. Frohnert BI, Hui TY, Bernlohr DA 1999 Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene. J Biol Chem 274:3970-3977
38. Benton CR, Koonen DP, Calles-Escandon J, Tandon NN, Glatz JF, Luiken JJ, Heikkila JJ, Bonen A 2006 Differential effects of contraction and PPAR agonists on the expression of fatty acid transporters in rat skeletal muscle. J Physiol 573:199-210
39. Verma NK, Singh J, Dey CS 2004 PPAR-gamma expression modulates insulin sensitivity in C2C12 skeletal muscle cells. Br J Pharmacol 143:1006-1013
40. Cazzolli R, Carpenter L, Biden TJ, Schmitz-Peiffer C 2001 A role for protein phosphatase 2A-like activity, but not atypical protein kinase C, in the inhibition of protein kinase B/Akt and glycogen synthesis by palmitate. Diabetes 50:2210-2218
41. Hue L, Taegtmeyer H 2009 The Randle cycle revisited: a new head for an old hat. Am J Physiol Endocrinol Metab 297:E578-E591
42. Zhang J, Fu M, Cui T, Xiong C, Xu K, Zhong W, Xiao Y, Floyd D, Liang J, Li E, Song Q, Chen YE 2004 Selective disruption of PPAR 2 impairs the development of adipose tissue and insulin sensitivity. Proc Natl Acad Sci USA 101:10703-10708
43. Askari B, Kanter JE, Sherrid AM, Golej DL, Bender AT, Liu J, Hsueh WA, Beavo JA, Coleman RA, Bornfeldt KE 2007 Rosiglitazone inhibits acyl-CoA synthetase activity and fatty acid partitioning to diacylglycerol and triacylglycerol via a peroxisome proliferator-activated receptor-γ-independent mechanism in human arterial smooth muscle cells and macrophages. Diabetes 56:1143-1152
44. Nakajima T, Iwasawa K, Oonuma H, Imuta H, Hazama H, Asano M, Morita T, Nakamura F, Suzuki J, Suzuki S, Kawakami Y, Omata M, Okuda Y 1999 Troglitazone inhibits voltage-dependent calcium currents in guinea pig cardiac myocytes. Circulation 99: 2942-2950
45. Brunmair B, Gras F, Neschen S, Roden M, Wagner L, Waldhäusl W, Fürnsinn C 2001 Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-γ-mediated changes in gene expression. Diabetes 50:2309-2315
46. Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR, Nicol CJ, Vinson C, Gonzalez FJ, Reitman ML 2003 Liver peroxisome proliferator-activated receptor γ contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 278:34268-34276
47. Matsusue K, Haluzik M, Lambert G, Yim SH, Gavrilova O, Ward JM, Brewer Jr B, Reitman ML, Gonzalez FJ 2003 Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest 111:737-747
48. Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, Ilkayeva O, Bain J, Stevens R, Dyck JR, Newgard CB, Lopaschuk GD, Muoio DM 2008 Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 7:45-56
49. Benton CR, Holloway GP, Han XX, Yoshida Y, Snook LA, Lally J, Glatz JF, Luiken JJ, Chabowski A, Bonen A 2010 Increased levels of peroxisome proliferator-activated receptor γ, coactivator 1α(PGC-1α) improvelipidutilisation,insulinsignallingandglucosetransport in skeletal muscle of lean and insulin-resistant obese Zucker rats. Diabetologia 53:2008-2019
50. Endo Y, Suzuki M, Yamada H, Horita S, Kunimi M, Yamazaki O, Shirai A, Nakamura M, Iso-O N, Li Y, Hara M, Tsukamoto K, Moriyama N, Kudo A, Kawakami H, Yamauchi T, Kubota N, Kadowaki T, Kume H, Enomoto Y, Homma Y, Seki G, Fujita T 2011 Thiazolidinediones enhance sodium-coupled bicarbonate absorption from renal proximal tubules via PPAR-dependent nongenomic signaling. Cell Metab 13:550-561
51. Macias-Gonzalez M, Moreno-Santos I, García-Almeida JM, Tinahones FJ, Garcia-Fuentes E 2009 PPARγ2 protects against obesity by means of a mechanism that mediates insulin resistance. Eur J Clin Invest 39:972-979